On May 11, 2026, Jill Fiedler-Kelly, the President of Services Solutions at Simulations Plus, Inc. (NASDAQ:SLP), executed a transaction involving the sale of 1,000 shares of the company's common stock. The total value realized from this sale was $16,530, with the shares being sold at a price point of $16.53 per share. This execution price was notably higher than the current market trading price of $13.57. It is also worth noting that the company's stock has experienced a 55% decline over the past year. The sale was carried out automatically under the framework of a Rule 10b5-1 trading plan.
Simultaneous with this sale, Ms. Fiedler-Kelly acquired 1,000 shares of Simulations Plus common stock. This acquisition was made through the exercise of employee stock options that were fully vested. These options, which have an expiration date set for February 23, 2027, were exercised at a price of $10.05 per share, resulting in a total cost of $10,050. Following the completion of these specific transactions, Ms. Fiedler-Kelly’s direct holdings consist of 77,817 shares of Simulations Plus, Inc. common stock and 8,400 employee stock options.
The timing of these insider movements coincides with a period of varied financial signals for the company. While Simulations Plus did not report profitability over the previous twelve-month period, analysts have projected that the firm will achieve profitability within the current year. Recent quarterly data shows that the company exceeded expectations for the second quarter of fiscal year 2026. Specifically, adjusted earnings per share reached $0.35, representing a 12.9% surprise over the anticipated $0.31. Revenue for the period was reported at $24.3 million, which surpassed forecasts by 12.19%.
Simulations Plus is also engaged in several high-level technical and research initiatives. The company has entered into a technical collaboration with Nvidia to incorporate AI capabilities and GPU-accelerated computing into its drug development modeling workflows. This initiative is designed to facilitate parallel exploration of model parameters and accelerate simulation cycles. Furthermore, the firm has initiated a funded research collaboration involving Lonza and the U.S. Food and Drug Administration (FDA) to create a predictive framework for assessing drug products regarding amorphous solid dispersion.
Despite these operational developments, the company faces headwinds in market sentiment from certain analysts. TD Cowen recently adjusted its price target for Simulations Plus downward to $16 from a previous target of $19, while maintaining a Hold rating. This adjustment was attributed to higher expected tax rates which are anticipated to impact earnings per share guidance. However, Simulations Plus has maintained its previously stated guidance for adjusted EBITDA and topline revenue for fiscal 2026.